Navigation Links
Adamis Pharmaceuticals CEO Provides Update for Shareholders
Date:5/3/2013

ur Beclomethasone-HFA product to initiate Phase III studies in asthma and COPD
  • Finalizing our allergic rhinitis product development in order to initiate Phase III clinical trials
  • Acquiring or in-licensing an established product or technology that, following regulatory marketing approvals, will compete in large (multi-billion dollar) product markets and will be synergistic with our existing assets.
  • On the Biotech side, we are focused on:

    • Completing our Phase I prostate cancer drug trial
    • Finalizing the activities necessary to begin a Phase I/II trial for our second prostate compound
    • Initiating a Phase II prostate cancer vaccine trial for TeloB-VAX.

    If we are able to complete additional financing transactions and make progress on our objectives, we intend to take the necessary steps to be in a position to list our common stock on a national stock exchange such as the NYSE-Amex or NASDAQ.  An up-listing could lead to an increase in shareholder value, give Adamis more market exposure, increase liquidity and partnering activities and increase our shareholder base to include more fundamental health care investors.

    I would like to thank all of our shareholders for their continued support and patience.  We will all do our very best to make Adamis a company that you will all be very proud of owning.

    Best regards,

    Dennis J. Carlo , Ph.D
    President and CEO

    About Adamis Pharmaceuticals Corporation

    Adamis Pharmaceuticals Corporation is a biopharmaceutical company engaged in the development and commercialization of specialty pharmaceutical and biotechnology products in the therapeutic areas of respiratory disease, allergy, oncology and immunology.  Products in its specialty pharmaceutical pipeline include the Epinephrine Injection PFS syringe for use in the emergency treatment of a
    '/>"/>

    SOURCE Adamis Pharmaceuticals Corporation
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4

    Related biology technology :

    1. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
    2. Valeant Pharmaceuticals Announces Extension of the Expiration Date for Its Previously Announced Tender Offer for All Outstanding Shares of Common Stock of Obagi Medical Products, Inc.
    3. VentiRx Pharmaceuticals Appoints James Kyle Bryan, M.D. as Chief Medical Officer
    4. Aurigenes Collaboration Programs with Endo Pharmaceuticals Reach Important Milestones
    5. Vanda Pharmaceuticals Appoints Dr. Paolo Baroldi As Chief Medical Officer
    6. Next Silicon Valley BioTalks Tackles “Is EDC Becoming a Commodity?” at Onyx Pharmaceuticals HQ
    7. Global Nuclear Medicine / Radiopharmaceuticals Market worth $5.55 Billion by 2017
    8. US Radiopharmaceuticals (USR) Awards Contract to Von Gahlen International for New Technetium-99m Generator Production Line Using Low Enriched Uranium Molybdenum-99
    9. Anthera Pharmaceuticals Reports 2012 Fourth Quarter And Fiscal Year Financial Results
    10. Savient Pharmaceuticals Reports Fourth Quarter and Year-End 2012 Financial Results
    11. New Opportunity: The Biomedical Innovations of Tomorrow - Research Report on PhotoMedex, Axiall Corp, Varian Medical Systems, Volcano Corporation and Navidea Biopharmaceuticals
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/1/2015)... Mass. , April 1, 2015  EMD Serono, ... Germany , announced today the appointment of ... Medical Affairs, Neurology and Immunology. In this capacity, he ... and business development projects and collaborations for Rebif ® ... and Neurology pipeline. Dr. Munschauer joins ...
    (Date:4/1/2015)... 1, 2015  Organovo Holdings, Inc. (NYSE MKT: ... delivering breakthrough 3D bioprinting technology, presented data on ... the 2015 Experimental Biology conference in ... represents an ideal extension of Organovo,s capabilities to ... useful in pharmaceutical research," said Keith Murphy ...
    (Date:4/1/2015)... BETHESDA, Md. , April 1, 2015 /PRNewswire/ ... development company committed to the fostering and monetization ... Markets LLC, a privately held full service global ... companies, recently issued an industry note featuring Spherix. ... McIlree , CFA, a Senior Analyst at Chardan, ...
    (Date:4/1/2015)... , April 1, 2015 ... company developing novel biological drugs to treat cancer, ... to announce the appointment of Christina Coughlin ... be responsible for providing medical and regulatory leadership ... Company. Dr. Coughlin has extensive experience ...
    Breaking Biology Technology:EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 2EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 3EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 4EMD Serono Appoints Frederick E. Munschauer M.D., FAAN to Vice President of Medical Affairs, Neurology and Immunology 5Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 2Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 3Organovo Describes First Fully Cellular 3D Bioprinted Kidney Tissue 4Chardan Capital Issues Industry Note Covering Spherix 2Chardan Capital Issues Industry Note Covering Spherix 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 2Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 3Immunocore Appoints Dr. Christina Coughlin as Chief Medical Officer 4
    ... Israel, December 2 InSightec Ltd. announced,today that ... with the ExAblate(R) system has the potential to ... have spread to,the bones (bone metastases). The results ... 11 online issue of Annals of Surgical Oncology, ...
    ... NicOx S.A.,(NYSE Euronext Paris: COX) today announced ... the commercial manufacture and supply of naproxcinod ... is NicOx, lead,investigational product and the first ... of,anti-inflammatory agents, which recently achieved positive results ...
    ... BASKING RIDGE, N.J., Dec. 2 Regado Biosciences, Inc., ... newly created position of Senior Vice President of Business ... McDonald brings to Regado nearly 20 years of experience ... operations, portfolio management and marketing. She will report ...
    Cached Biology Technology:New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 2New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 3New Publications Show Noninvasive Magnetic Resonance-Guided Focused Ultrasound to be a Potentially Safe, Effective Pain-Relieving Treatment for Bone Metastases 4NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 2NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 3NicOx Signs Agreement With DSM for the Commercial Manufacture of Naproxcinod Drug Substance 4Ellen McDonald Joins Regado Biosciences as Senior Vice President of Business Operations and Chief Business Officer 2
    (Date:3/23/2015)... BOSTON, Mass , March 23, 2015 SoundView ... shipment of NXT-ID,s (NASDAQ: NXTD ) Wocket smart wallet. SoundView ... world user feedback on their experience with the Wocket in ... experience at CVS, Whole Foods and other retailers, making both ... Kris Tuttle also says, "If the company meets ...
    (Date:3/20/2015)... Mar. 19, 2015 Research and Markets ( ... Geometry - Global Strategic Business Report" report to their ... Hand Geometry in US$ Thousands. The report provides separate comprehensive ... Japan , Europe , ... and Rest of World. Annual estimates and forecasts ...
    (Date:3/17/2015)... 17, 2015 MedNet Solutions , ... clinical study management systems, is pleased to announce ... ARENA,s Outsourcing in Clinical Trials Southeast conference – ... an excellent forum for MedNet to showcase ... software-as-a-service (SaaS) eClinical technology platform. We ...
    Breaking Biology News(10 mins):Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 2Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 3Hand Geometry - Global Strategic Business Report 2015: An Essential Security Component for both Government & Enterprise Sector 4Connect With MedNet Solutions At Outsourcing In Clinical Trials Southeast 2
    ... SALT LAKE CITYLeukemia is the most common childhood cancer; ... zebrafish at Huntsman Cancer Institute (HCI) at the University ... in T-cell acute lymphocytic leukemia (T-ALL), according to an ... research journal Oncogene . When compared to samples ...
    ... to humans, the bacteria and tiny plants living in the ... is quite different than ours for one, they can,t ... red meat for a pick-me-up. So where does their ... " points to a source on the seafloor: minute particles ...
    ... a specific sugar residue on the cell surface, which is ... Faissner has now been able to use LewisX for the ... researchers report on their results in the Journal of ... Antibodies that recognise the LewisX sugar residue are used routinely ...
    Cached Biology News:Zebrafish models identify high-risk genetic features in leukemia patients 2As good as gold 2
    ... The iEMS Incubator/Shaker HT is ... the iEMS Incubator/Shaker HT is ... DNA hybridization and primer extension ... available as a one-cabinet model, ...
    ... Description: Beta-Agarase is useful in recovering ... agarose. Beta-Agarase digests the agarose into ... Properties: Heat Inactivation: 65C, 15 min ... 6.5 Purity: Tested for contaminating endonucleases, ...
    ... called a ?cap? is present on ... mRNAs and many viral RNAs. Substitution ... of the GTP present in an ... the synthesis of transcripts with a ...
    ... oligonucleotides: PTOs are internucleotide modifications, ... backbone is replaced by a sulphur atom. ... degradation. PTOs are available as ... Oligonucleotides with thio-caps ...
    Biology Products: